Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New diuretic protocol aims to improve heart failure treatment safety

NCT ID NCT03892148

Disease control Sponsor: University Hospital, Clermont-Ferrand Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether a step-by-step plan for using diuretics (water pills) is better and safer than usual care for people hospitalized with worsening chronic heart failure. The trial involved 299 adults and compared a structured protocol using furosemide and hydrochlorothiazide against standard non-protocolized practice. Researchers measured changes in kidney function and weight to see if the protocol reduced complications like kidney injury.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Furosemide and hydrochlorothiazide (diuretics)
What this could lead to
If successful, this could establish a safer, more effective way to manage fluid buildup in chronic heart failure patients, reducing hospital stays and kidney damage.
What could go wrong
This is a completed Phase 4 trial with 299 participants, but the protocol may not work for all patients or settings. Risks include kidney injury and electrolyte imbalances.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

299 people

The number who actually took part.

Started

May 2019

Finished

Jan 2023

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult patients hospitalized for chronic decompensated congestive heart failure without acute pulmonary edema and acute cardiac decompensation against a background of hypertensive crisis * covered under a social security program * with legal capacity to give voluntary informed consent to participate in the study Exclusion Criteria: * First episode of decompensated congestive heart failure * Protocolized shock or hypotension (\<90 mmHg blood pressure) managed or requiring nitrovasodilators or non-invasive ventilation * One of the following cardiovascular pathologies: acute myocardial infarction / cardiac tamponade / aortic dissection / acute pulmonary embolism / heart transplant / ventricular assist device / acute pulmonary edema / hypertensive crisis * More than 12h of intravenous diuretics administered prior to inclusion * Generalized edema caused by cirrhosis or nephrotic syndrome * Requiring pleural or peritoneal tap for therapeutic purposes * Patient allergic or intolerant to furosemide and on long-term bumetanide use * Patient in dialysis or end-stage chronic kidney disease (CKD-EPI-calculated GFR \<15 mL/min/1.73m²) or acute kidney injury of known non-cardiac cause * Severe hypokalemia (\< 3 mmol/L) on admission * Patient who is pregnant, breastfeeding, or of childbearing age not on effective contraception * Adult patient safeguarded under court protection measures (guardianship, wardship, or judicial protection)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute heart failure are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

congestive heart failure heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute heart failure Chronic heart failure Heart failure

Contacts and locations

Locations

  • CH PUY

    Le Puy-en-Velay, France

  • CH RIOM

    Riom, France

  • CHU de GRENOBLE

    Grenoble, France

  • Ch Annecy

    Annecy, France

  • Ch Issoire

    Issoire, France

  • Ch Lyon Sud

    Lyon, France

  • Ch Moulins

    Moulins, France

  • Chu Clermont-Ferrand

    Clermont-Ferrand, 63003, France

  • Infirmerie Protestante de Lyon

    Lyon, 69300, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.